生物制药公司Arvinas（ARVN）今日盘中股价大幅下跌11.96%，主要原因是公司发布的季度财报未能达到市场预期。
根据Arvinas公布的最新季度报告，截至6月30日的季度调整后每股亏损为0.84美元，虽然好于分析师平均预期的每股亏损1美元，但仍远低于去年同期的表现。公司当季营收为2240万美元，同比大幅下降70.7%，且未达到分析师预期的3037万美元。此外，公司本季度净亏损达6120万美元。
尽管财报表现不佳，但华尔街分析师对Arvinas仍保持相对乐观态度。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为14美元，较最新收盘价高出约45.6%。然而，投资者似乎对公司短期内的业绩表现持谨慎态度，导致股价出现大幅下跌。值得注意的是，Arvinas股价今年以来已累计下跌60.3%，显示出投资者对公司长期发展前景的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.